31.07.19: Not intended for U.S. and UK Media
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancerDarolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADTmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 31, 2019 Category: Pharmaceuticals Source Type: news
30.07.19: Second quarter of 2019:
Bayer on track in operational businessGroup sales increase by 0.9 percent (Fx & portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx & portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 p...
Source: Bayer IR Newsfeed: Events - July 30, 2019 Category: Pharmaceuticals Source Type: news
26.07.19: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in EuropeRecommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe with a tumor-agnostic indication / CHMP opinion is based on pooled data showing that larotrectinib provides high and durable responses in adult and pediatric patients with TRK fusion cancer, including CNS tumors / Larotrectinib showed a favora...
Source: Bayer IR Newsfeed: Events - July 26, 2019 Category: Pharmaceuticals Source Type: news
22.07.19: Yellow Wood Partners to acquire iconic Dr. Scholl's™ brand from Bayer
Yellow Wood Partners to acquire iconic Dr. Scholl's™ brand from Bayermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 22, 2019 Category: Pharmaceuticals Source Type: news
18.07.19: Not intended for U.S. and UK Media
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancerCombination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trialmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 18, 2019 Category: Pharmaceuticals Source Type: news
30.07.19: Q2 2019 Investor Conference Call
Q2 2019 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2019 Category: Pharmaceuticals Source Type: news
16.07.19: Start of Quiet Period
Start of Quiet PeriodAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 15, 2019 Category: Pharmaceuticals Source Type: news
08.07.19: Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolismPhase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prev...
Source: Bayer IR Newsfeed: Events - July 8, 2019 Category: Pharmaceuticals Source Type: news
02.07.19: LEO Pharma completes the acquisition of Bayer's prescription dermatology business
LEO Pharma completes the acquisition of Bayer's prescription dermatology businessmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 2, 2019 Category: Pharmaceuticals Source Type: news
01.07.19: Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platform
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platformCreated by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatmentsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 1, 2019 Category: Pharmaceuticals Source Type: news
26.06.19: Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg
as mediator
Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg
as mediator mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 26, 2019 Category: Pharmaceuticals Source Type: news
21.06.19: Not intended for U.S. and UK Media
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infantsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 21, 2019 Category: Pharmaceuticals Source Type: news
19.06.19: Not intended for U.S. and UK Media
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trialGBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as...
Source: Bayer IR Newsfeed: Events - June 19, 2019 Category: Pharmaceuticals Source Type: news
05.06.19: Roadshow Los Angeles (CA), U.S.A.
Roadshow Los Angeles (CA), U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news
01.08.19: Crop Science Summer Technology Showcase Day 1 (Chesterfield Research Center), St. Louis, MO, U.S.A.
Crop Science Summer Technology Showcase Day 1 (Chesterfield Research Center), St. Louis, MO, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news
